Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 00:37 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Role of EndoFLIP in the Diagnostic Paradigm of Esophagogastric Junction Outflow Obstruction
NCT04938102 · University of Kansas Medical Center · NA · withdrawn · last registry update 2024-10-21 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Administrative-not IRB approved” | – | Registry record, University of Kansas Medical Center |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against SNAP25 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-10-07Phase 3 first posted: Merz Aesthetics GmbH, NT 201 + NT 201 Placebo (NCT07210463)
- 2025-09-10Also stopped (withdrawn): Lille Catholic University, Botulinum Toxin Type A 100U + Botulinum Toxin Type A 200U (NCT03726788)
- 2025-09-09Results posted on the registry: Allergan, OnabotulinumtoxinA X + Placebo (NCT05100199)
- 2025-09-05Also stopped (withdrawn): University Hospitals Cleveland Medical Center, Intravesical Botox injection (NCT05393921)
- 2025-08-20Results posted on the registry: Mayo Clinic, a drug against SNAP25 (NCT04448171)
- 2025-08-20Also stopped (terminated): Mayo Clinic, a drug against SNAP25 (NCT04448171)
- 2025-08-14Phase 3 first posted: Merz North America, Inc., NT 201 + NT 201 Placebo (NCT07122193)
- 2025-08-06Results posted on the registry: AbbVie, BOTOX (NCT06218251)
- 2025-07-18Also stopped (withdrawn): Montefiore Medical Center, Phenazopyridine + 1% lidocaine with sodium bicarbonate (NCT06514430)
- 2025-07-16Results posted on the registry: Allergan, OnabotulinumtoxinA X + Placebo (NCT05152576)
- 2025-06-27Results posted on the registry: Allergan, Formulation A: OnabotulinumtoxinA + Formulation B: OnabotulinumtoxinA (NCT05013424)
- 2025-06-27Phase 3 first posted: Oslo University Hospital, CGRP mAbs and onabotulinumtoxin A + CGRP mAbs and placebo (NCT07040813)
- 2025-06-17Results posted on the registry: Allergan, BOTOX (NCT04609020)
- 2025-06-12Phase 3 first posted: Merz Therapeutics GmbH, Xeomin + Placebo (NCT07018700)
- 2025-06-12Phase 3 first posted: Merz Therapeutics GmbH, Xeomin + Placebo (NCT07018713)
- 2025-06-10Phase 3 first posted: Daewoong Pharmaceutical Co. LTD., DWP712 inj. + Botox® 100 Units (NCT07013279)
- 2025-06-10Phase 3 first posted: University Hospital, Bordeaux, Botulinum toxin injection (NCT07013240)
- 2025-06-05Results posted on the registry: Croma-Pharma GmbH, Botulinum Toxin A + Placebo (NCT03985982)
- 2025-05-29Phase 3 first posted: Nantes University Hospital, Xeomin + Placebo (NCT06995287)
- 2025-05-13Results posted on the registry: OHSU Knight Cancer Institute, Botulinum Toxin Type A (NCT04965311)
- 2025-05-13Also stopped (terminated): OHSU Knight Cancer Institute, Botulinum Toxin Type A (NCT04965311)
- 2025-05-09Results posted on the registry: The Methodist Hospital Research Institute, a drug against SNAP25 (NCT06059066)
- 2025-05-06Results posted on the registry: AbbVie, Botulinum Toxin Type A (NCT04073303)
- 2025-04-27Phase 3 first posted: Espad Pharmed, Abobotulinumtoxin A (Espad Pharmed Darou Co.) + Abobotulinumtoxin A (Ipsen Co.) (NCT06946160)
- 2025-04-24Phase 3 first posted: Region Stockholm, 5U/0,1 ml Botulinum toxin A + 10U/0,1 ml Botulinum toxin A (NCT06941636)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision